Sponsored · Video
Incysus Enters Clinical Trial for Genetically-Modified T Cells for Treating Glioblastoma
Lawrence Lamb, Executive VP and Chief Scientific Officer at Incysus Therapeutics, tells an inspirational story about the impetus behind the immuno-oncology company’s formation to advance a unique and innovative approach to treating solid tumor cancers using multiple mechanisms of tumor resistance and immunosuppression. Incysus has received clearance to conduct a Phase I trial using gamma delta T cell infusion toward developing “off-the-shelf” cell therapies. The company is also beginning a trial of their DRI platform for treatment of patients with newly-diagnosed glioblastoma, the first genetically modified gamma delta T cell product candidate cleared to enter the clinic.